News & Updates
Filter by Specialty:
Low-intensity shockwave with PDE-5i safe, effective for erectile dysfunction
The combination of low-intensity shockwave therapy (Li-ESWT) with phosphodiesterase 5 inhibitor (PDE-5i) medication safely improves erectile function in vasculogenic erectile dysfunction (ED) patients who had failed first-line oral therapy, a recent study has found.
Low-intensity shockwave with PDE-5i safe, effective for erectile dysfunction
29 Sep 2021
Add-on metoprolol of no benefit to high-risk prostate cancer patients
Use of metoprolol among high-risk prostate cancer patients receiving androgen deprivation therapy does not appear to improve oncological outcomes, as shown in a study.
Add-on metoprolol of no benefit to high-risk prostate cancer patients
29 Sep 2021
Inhaled JAK inhibitor cuts exhaled nitric oxide in mild asthma
GDC-0214, an inhaled Janus kinase (JAK) inhibitor, induces dose-dependent reductions in fractional exhaled nitric oxide in patients with mild asthma, a recent study has found.
Inhaled JAK inhibitor cuts exhaled nitric oxide in mild asthma
29 Sep 2021
Palbociclib plus letrozole prolongs survival in Asian patients with advanced breast cancer
Palbociclib plus letrozole as first-line treatment improves progression-free survival (PFS) vs placebo plus letrozole in postmenopausal Asian patients with advanced oestrogen receptor (ER)–positive and HER2-negative breast cancer (BC), primary results of the phase III PALOMA-4 study have shown.
Palbociclib plus letrozole prolongs survival in Asian patients with advanced breast cancer
29 Sep 2021
High cEPC counts tied to worse anxiety, depression in MDD patients
Elevated counts of circulating endothelial progenitor cells (cEPCs) are correlated to worse anxiety, more severe depressive symptoms, poorer cognitive performance, greater social disability, and impaired overall mental health in patients with major depressive disorder (MDD), a recent study has found.
High cEPC counts tied to worse anxiety, depression in MDD patients
28 Sep 2021
DPP-4–to–SGLT2 inhibitor switch confers multiple benefits for patients with diabetes, hypertension
In the treatment of patients with type 2 diabetes mellitus and hypertension, switching from a dipeptidyl peptidase-4 (DPP-4) inhibitor to the sodium-glucose cotransporter-2 (SGLT2) inhibitor luseogliflozin appears to have favourable effects on blood pressure (BP), circadian rhythm, and night-time systolic BP (SBP) and pulse rate (PR), according to data from the open-label LUNA trial.
